Syngen Biotech Statistics

Total Valuation

Syngen Biotech has a market cap or net worth of TWD 3.51 billion. The enterprise value is 3.70 billion.

Market Cap	3.51B
Enterprise Value	3.70B

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Syngen Biotech has 27.10 million shares outstanding. The number of shares has increased by 0.01% in one year.

Current Share Class	n/a
Shares Outstanding	27.10M
Shares Change (YoY)	+0.01%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	8.15%
Owned by Institutions (%)	4.23%
Float	10.54M

Valuation Ratios

The trailing PE ratio is 14.70.

PE Ratio	14.70
Forward PE	n/a
PS Ratio	1.75
PB Ratio	1.61
P/TBV Ratio	1.63
P/FCF Ratio	13.80
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.98, with an EV/FCF ratio of 14.54.

EV / Earnings	15.49
EV / Sales	1.85
EV / EBITDA	8.98
EV / EBIT	12.23
EV / FCF	14.54

Financial Position

The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.19.

Current Ratio	2.21
Quick Ratio	1.50
Debt / Equity	0.19
Debt / EBITDA	1.01
Debt / FCF	1.64
Interest Coverage	32.64

Financial Efficiency

Return on equity (ROE) is 11.22% and return on invested capital (ROIC) is 7.24%.

Return on Equity (ROE)	11.22%
Return on Assets (ROA)	6.30%
Return on Invested Capital (ROIC)	7.24%
Return on Capital Employed (ROCE)	12.06%
Revenue Per Employee	8.10M
Profits Per Employee	966,668
Employee Count	247
Asset Turnover	0.66
Inventory Turnover	4.04

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.08% in the last 52 weeks. The beta is 0.43, so Syngen Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.43
52-Week Price Change	-15.08%
50-Day Moving Average	127.37
200-Day Moving Average	140.37
Relative Strength Index (RSI)	56.89
Average Volume (20 Days)	11,690

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Syngen Biotech had revenue of TWD 2.00 billion and earned 238.77 million in profits. Earnings per share was 8.81.

Revenue	2.00B
Gross Profit	707.90M
Operating Income	305.10M
Pretax Income	298.53M
Net Income	238.77M
EBITDA	398.71M
EBIT	305.10M
Earnings Per Share (EPS)	8.81

Full Income Statement

Balance Sheet

The company has 228.31 million in cash and 416.72 million in debt, giving a net cash position of -188.41 million or -6.95 per share.

Cash & Cash Equivalents	228.31M
Total Debt	416.72M
Net Cash	-188.41M
Net Cash Per Share	-6.95
Equity (Book Value)	2.18B
Book Value Per Share	80.54
Working Capital	571.72M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 341.76 million and capital expenditures -87.51 million, giving a free cash flow of 254.26 million.

Operating Cash Flow	341.76M
Capital Expenditures	-87.51M
Free Cash Flow	254.26M
FCF Per Share	9.38

Full Cash Flow Statement

Margins

Gross margin is 35.39%, with operating and profit margins of 15.25% and 11.94%.

Gross Margin	35.39%
Operating Margin	15.25%
Pretax Margin	14.92%
Profit Margin	11.94%
EBITDA Margin	19.93%
EBIT Margin	15.25%
FCF Margin	12.71%

Dividends & Yields

This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.86%.

Dividend Per Share	5.00
Dividend Yield	3.86%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	56.75%
Buyback Yield	-0.01%
Shareholder Yield	3.85%
Earnings Yield	6.80%
FCF Yield	7.24%

Dividend Details

Stock Splits

The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.

Last Split Date	Jul 9, 2018
Split Type	Forward
Split Ratio	1.1

Scores

Syngen Biotech has an Altman Z-Score of 4.86.

Altman Z-Score	4.86
Piotroski F-Score	n/a